secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001842952-24-000033
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics raises ~$100M via private placement; FDA clears IND for CTIM-76
--------------------------------------------------------------------------------

- Private placement raises ~$100M gross via 64.5M shares/pre-funded warrants at $1.55/share.
- FDA cleared IND for CTIM-76 (CLDN6 x CD3 bispecific) for Phase 1 in CLDN6-positive gynecologic/testicular cancers.
- First patient enrollment for dose escalation expected mid-2024; Phase 1 study to enroll up to 70 patients.
- Proceeds plus existing cash extend cash runway into 2028, covering estimated Phase 1 trial duration.
- Private placement led by Nextech, with participation from Ally Bridge, Avidity, Blackstone, Blue Owl, etc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000184295224000033/0001842952-24-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000184295224000033/cntx-20240501.htm
  HTML page:      https://secwatch.observer/filing/0001842952-24-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer